Huaren Health: The application for the registration and marketing authorization of Furmaric Acid Voronol Tablets has been accepted
Huaren Health's wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application for Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration. This new drug is a potassium ion competitive acid blocker that can effectively inhibit gastric acid secretion without relying on an acidic environment, significantly reducing the occurrence of nighttime gastric acid elevation
According to the Zhitong Finance APP, Huaren Health (301408.SZ) announced that its wholly-owned subsidiary Jiangsu Shenhua Pharmaceutical Co., Ltd. has received the "Acceptance Notice" for the drug registration application of Fumaric Acid Vonoprazan Tablets issued by the National Medical Products Administration. Fumaric Acid Vonoprazan Tablets are a new type of potassium ion competitive acid blocker (P-CAB), which can reversibly inhibit the H+/K+-ATPase on gastric parietal cells in a potassium ion competitive manner without relying on an acidic environment. It is relatively stable in a strongly acidic environment and can quickly, effectively, and durably inhibit gastric acid secretion from parietal cells, significantly reducing the occurrence of nighttime gastric acid elevation
